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Abstract 
A fast, simple and sensitive micellar enhanced spectrofluorimetric method is 
performed for the determination of Daclatasvir dihydrochloride (DAC) in its 
pharmaceutical dosage form and in spiked human plasma. The fluorescence 
intensity (FI) was measured at 367 nm after excitation at 300 nm.  In aqueous 
solution, the FI of DAC was greatly enhanced by more than 110% in the presence 
of sodium dodecyl sulphate (SDS). The detection method was linear over the 
range of 12.93 to 161.60 ng/mL, with a limit of detection of 1.75 ng/mL. The 
proposed method was successfully applied to the determination of DAC in its 
pharmaceutical dosage form and the mean % recovery of DAC in spiked human 
plasma was 95.42 + 2.52. The developed methodology was also extended to stress 
studies of DAC after exposure to different forced degradation conditions 
including acidic, alkaline, photolytic, thermal and oxidative environments. 
 
Keywords: Daclatasvir dihydrochloride (DAC) detection, Spectrofluorimetry;  
spiked human plasma. 
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1. Introduction 
Hepatitis C virus (HCV) infection rates are approximately 130 million people 
with the majority suffering from chronic infections as chronic liver disease, 
cirrhosis and hepatocellular carcinoma.  Mortality because of HCV infection is a 
main cause of death among HIV-positive patients and one of the highest HCV 
infection rates (15-20%) has been reported from Egypt [1-3].  
(HCV) treatment has achieved significant advances with the help of new direct-
acting antivirals. Nucleotide polymerase inhibitors are a class of the new 
treatment that have been proven to be highly effective and safe as part of an 
antiviral regimen [4]. Daclatasvir (DAC) (Fig. 1) Methyl[(2S)-1-[5]-2-
pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-
pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate is a highly effective and 
selective direct acting antiviral of HCV [6], and is specifically active against 
NS5A, a non-structural protein encoded by HCV. DAC binds to the N-terminus 
of NS5A within domain 1 of the protein, inhibiting both viral RNA replication 
and virion assembly resulting in structural distortions that interfere with NS5A 
functions.  DAC was approved for use in combination with other antiviral agents 
as a therapy for chronic hepatitis C in the United States in 2015 [7]. Current 
indications are limited to patients with HCV genotype 3, although several studies 
have shown that DAC is also active against other HCV genotypes [8]. 
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Figure 1. Chemical structure of Daclatasvir Dihydrochloride 
(C40H52Cl2N8O6). 
 
In this article, we introduce a new fluorescent-based assay capable of sensitively 
and specifically detecting DAC in pharmaceutical dosage form and in spiked 
human plasma. This compares to the relatively few literature reports which 
describe the use of high performance liquid chromatography [9-11], liquid 
chromatography-mass spectrometry (LC-MS) [5, 12], electrochemistry [13] and 
spectrophotometry  [14, 15] for DAC determination. To the best of our 
knowledge, a spectrofluorimetric method for DAC determination has been 
reported only once recently [16] and did not analyse DAC in the presence of its 
degradation products. This motivated us to develop and validate a stability 
indicating spectrofluorimetric assay for the quality control of DAC in 
pharmaceutical dosage form and spiked human plasma by introducing a micellar 
enhancement of the native fluorescence intensity (FI) of DAC. A simple and 
highly sensitive spectrofluorimetric method has been developed for the 
determination of DAC in pure form, tablets and in spiked plasma.  Micellar media  
allows  increasing the FI of target fluorophores by lowering the limit of detection 
and thus increasing their sensitivity [17]. Sodium dodecyl sulphate (SDS), has 
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been used for the determination of many pharmaceutical compounds [18-20]. The 
critical micelle concentration (CMC) of SDS in pure water at 25 °C is 8.2 × 10-3 
M and the aggregation number at this concentration is usually considered to be 
62 [21]. The method developed here is simple, time-saving and does not require 
a tedious multi-step procedure.  Another significant advantage is avoiding the use 
of volatile and corrosive organic solvents for target extraction. The performance 
of the micellar enhanced spectrofluorimetric method was validated with the aim 
of demonstrating the potential for direct analysis of human samples at clinically 
relevant concentrations.  
 
 
2. Experimental: 
2.1 Instruments 
The fluorescence spectra and measurements were obtained using a JASCO FP 
6200- Spectrofluorimeter equipped with a 150 W xenon lamp, a recorder and 
using a 1.0 cm quartz cell. Instrument excitation and emission slits were both 
adjusted to 5 nm. Spectra were evaluated using Spectra Manager FP-6200 Control 
Driver software, Version 1.54.03 [Build 1], JASCO Corporation.              
 
2.2 Materials and reagents 
2.2.1 Pure materials 
DAC purity (99.2%) batch number (PO-20131121-01) was kindly supplied from 
NODCAR (Cairo, Egypt). 
 
2.2.2.  Pharmaceutical dosage form 
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Daklanork® tab (MSD, Egypt), Batch no. M1010417, 65.92 mg Daclatasvir 
dihydrochloride equivalent to 60 mg DAC/tab, was purchased from the local 
market.  
 
2.2.3. Chemicals and Reagents 
Sodium dodecyl sulfate (SDS) (Riedel–de Haen, Germany), 1.0 % (W/V) 
aqueous solution was prepared by dissolving 1.0 g SDS in distilled water, and 
then diluting to 100 mL with the same solvent. The solution was kept stable for 
at least 7 days when left in a refrigerator. β-cyclodextrin (β-CD) was obtained 
from Merck (Germany), 0.5 % (W/V) aqueous solution was prepared by 
dissolving 0.5 g β-CD in distilled water, and then it was diluted to100 mL with 
the same solvent. Phosphate buffer [potassium phosphate monobasic] was 
obtained from (Sigma, Germany), and prepared at 10 mM aqueous solution pH 
7.0 ±0.2. Methanol (HPLC grade 99.9%), 2-propanol (HPLC grade 99.9%), 
ethanol (HPLC grade 99.8%), acetonitrile (HPLC grade 99.9%), hydrochloric 
acid (HPLC grade 37%) 1.0 M aqueous solution prepared were all purchased 
from Sigma-Aldrich, Germany. Sodium chloride and sodium hydroxide pellets 
(1.0 M aqueous solution prepared) were obtained from Winlab, Leicestershire, 
U.K. Fresh human plasma samples were obtained from NODCAR (Cairo, Egypt) 
and were kept frozen until use after gentle thawing.  Double distilled water was 
used throughout all experiments. 
 
2.3. DAC Solutions 
2.3.1. Standard stock solution  
Stock 1: A stock standard solution of DAC reference standard (400 µg/mL) was 
prepared by dissolving 10 mg standard DAC in double distilled water and the 
volume was completed to 25 mL using the same solvent.  
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Stock 2: 1 mL of stock 1 was transferred into a 25 mL volumetric flask (16 
µg/mL)   and then completed to the mark with the same solvent. 
2.3.2. Standard working solution  
A DAC working standard solution (640 ng/mL) was prepared by transferring 1 
mL of stock 2 solution into a 25 mL volumetric flask and completing to the mark 
with water.  
 
2.4.  Procedures 
 
2.4.1.  Construction of the Calibration Curves. 
Aliquots from DAC working solution equivalent to 12.93-161.60 ng DAC were 
carefully transferred into a series of 10-mL volumetric flasks. Then 2.0 mL 1 % 
SDS solution were added to each flask. The volume was completed with distilled 
water; the contents of the flasks were mixed well. A blank experiment was 
performed simultaneously, and the fluorescence spectra were recorded intensity 
after excitation at 300 nm. The fluorescence intensities were measured at 368 nm 
and plotted against the final drug concentrations (ng/mL) to obtain the calibration 
graph. Alternatively, the corresponding regression equation was derived.  
 
2.4.2. Procedure for Tablet analysis 
Ten tablets were weighed and grinded to a fine powder. An amount of the ground 
tablet weight equivalent to 10 mg Daclatasvir HCl was accurately weighed, 
transferred to a 25-mL volumetric flask and dissolved in double distilled water. 
After sonication for 30 min the volume was diluted with double distilled water. 
The produced solution (400 μg/mL) was filtered with a 0.45 µm disposable 
syringe filter and then diluted to obtain an aqueous stock solution (16 μg/mL). 
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Aliquots from working solution covering the concentration range were 
transferred into a series of 10-mL volumetric flasks, the ‘Procedure for calibration 
graph’ was then performed. The tablet content was determined from the 
previously plotted calibration graph. 
 
2.4.3. Procedures for spiked human plasma 
One mL of thawed human plasma were transferred into a centrifuge tube, diluted 
with 1 mL of 0.1, 0.31 and 0.52 µg DAC and deproteinized with 2 mL ACN, then 
vortex mixing. Final concentrations were 25.00, 77.60 and 129.28 ng/mL DAC. 
The solutions were centrifuged at 5000 rpm for 15 minutes. The solutions were 
then filtered through a disposable syringe filter (0.45 µm) and the same procedure 
as described for the production of the calibration graph was followed. The 
experiment was carried out and each solution was prepared in triplicate. The 
concentration of DAC in plasma was then calculated based on the calibration plot.   
 
2.4.4.  Procedures for stability indicating assay 
Intended degradation was performed using acid hydrolysis, base hydrolysis, 
oxidative degradation, thermal degradation and sunlight degradation. A 
degradation sample was prepared by transferring an accurately weighed amount 
of the tablets corresponding to 10 mg of DAC declared active principle into 100 
mL volumetric flasks, diluted with distilled water and sonicated for 30 mins. Then 
4 mL of this solution was taken in each of five 100 mL round bottomed flasks to 
perform the degradation tests. 0.1 N of each HCL and NaOH were enough to 
assess the degradation behaviour. To the first flask, 10 mL of 0.1 N HCl was 
added for acidic degradation. To the second flask, 10 mL of 0.1 N NaOH was 
added for basic degradation. To the third flask, 10 mL of 30 % (v/v) H2O2 was 
added for oxidative degradation. the fourth flask was diluted with the distilled 
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water and heated at 70 ºC in a water bath. The fifth flask was diluted with distilled 
water and left in sunlight. After the required time, samples were treated as 
follows: the pH values of the first and second flasks were neutralized with 1N  
NaOH and 1 N HCl, respectively and then the first three flasks were diluted with 
double distilled water to the mark. The solutions were filtered through a 
disposable syringe filter (0.45 µm) and then serially diluted to the required 
volume with double distilled water. Two mL of the resulting solutions was then 
transferred into 10 mL volumetric flasks to obtain a concentration of 160 ng/mL 
DAC and the procedure described above (section 2.4.1) was performed. The 
nominal content of the aliquots was calculated from the calibration graph. 
 
Results and Discussion 
 
A stability-indicating micellar enhanced spectrofluorimetric method was 
developed and fully validated for the determination of DAC with several 
experimental parameters accurately tested and optimized. The absorption and 
fluorescence emission spectra of DAC are shown in Figure 2 with the native 
fluorescence of DAC measured at an excitation wavelength (λex) of 300 nm. The 
fluorescence of DAC is characterized by two emission peaks at 351 nm and 368 
nm, exhibiting a fluorescence intensity depending on the microenvironment as 
seen in Figure 3. It is worth mentioning that the distinct shoulder at 351 nm in 
Figure 3 appears only when DAC is in micellar media. The literature revealed 
that this shoulder peak is attributed to the intercalation of polyaromatic 
compounds within SDS containing media (SDS concentration ≥ 4 mM) as a 
consequence of very weak Л-Л interaction due to the incorporation of DAC into 
the micelle [22]. 
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3.1. Optimization of the experimental conditions  
Various experimental parameters affecting the native FI of the drug and its 
stability were systematically studied. Such factors include the effect of different 
diluting solvents as well as different buffers and surfactants.  
 
 
Figure 2. Absorption and emission spectra for 90 ng/mL aqueous DAC in SDS 
micellar media. 
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Figure 3. Fluorescence emission spectra of 90 ng/mL DAC in water and in 
aqueous SDS after excitation at 300 nm. 
 
 
3.1.1. Effect of excitation wavelength 
 The fluorescence intensity of DAC in water after excitation at 300 nm is higher 
than when being excited at 317 nm (DAC ƛ max ) , as shown in Figure 4. Therefore, 
300 nm was chosen to be the excitation wavelength.  
 
Figure 4. Effect of excitation wavelength on the fluorescence intensity of 40 
ng/ml DAC. 
 
3.1.2.Effect of diluting solvent 
The effect of different diluting solvents (methanol, ethanol, water, 2-
propanol and acetonitrile) on the FI of DAC was studied. As shown in 
Figure 5, the FI of the studied drug in methanol is slightly higher in 
comparison with water, but water was selected as the optimum diluting 
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solvent because it is an environmentally friendly solvent, inexpensive, 
readily available. This circumvents the environmental problems 
associated with organic solvents resulting in both economic and 
greener chemistry advantages in support of the developed method.  
 
Thus, using toxic, flammable, or environmentally damaging solvents 
would appear needless because this has no special impact on the DAC 
fluorescence signal intensity compared to water which has nearly the 
same FI at 300 nm excitation as the organic solvents 
compared.  Chemists are advised to examine whether they can achieve 
similar special chemical results while at the same time minimizing the 
environmental impact associated with many solvents[23, 24]. As a 
result, water was subsequently used in this project.  
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Figure 5. Effect of solvents on the FI of a 30 ng/mL DAC solution. 
 
 
3.1.3.  Effect of surfactants 
The effect of different types of surfactants (SDS, β-CD and Tween 80) on the 
fluorescence intensity of DAC was investigated. Tween 80 caused a significant 
decrease in the FI while the addition of SDS caused an enhancement (about 
110%) of the FI compared with aqueous solution only. This may be as a result of 
light scattering by SDS micelles. On the other hand, β-cyclodextrin showed no 
marked effect on the FI of DAC, as shown in Figure 6. Therefore, SDS was used 
as a fluorescence enhancer to develop a new micellar enhanced 
spectrofluorimetric method for the determination of DAC in its pure form, dosage 
form and in spiked human plasma. 
 
 
Figure 6. Comparing the effect of 1% (w/v) SDS, 0.5 % (w/v) (β-CD)  and Tween 
20 on the FI of an aqueous solution of 30 ng/mL DAC. 
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3.1.4. Effect of pH  
The influence of pH on the fluorescence intensity of DAC was studied using 10 
mM phosphate buffer covering a pH range of 2 to 9. It was found that the highest 
FI was obtained at pH 7 and lower FI’s observed at both more acidic and basic 
pH values (see Figure 7). Importantly, there was little variation in FI between pH 
7 buffer and water only. This establishes the optimum conditions as being in 
water without pH adjustment.  
 
 
 
Figure 7. Effect of pH on the FI of a 30 ng/mL aqueous solution of DAC. 
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3.1.5. Effect of SDS concentration 
 
The influence of SDS concentration on the FI of DAC was studied using 
increasing volumes of 1.0% w/v SDS. It was found that increasing SDS 
concentration (0.69-17.25 mM) resulted in a consequent increase in FI up to 
6.9 mM. Beyond this concentration, a decrease in the FI was observed 
(Figure 8). Therefore, 6.90 mM SDS solution was chosen as the optimum 
SDS concentration to achieve maximum enhancement in the FI of DAC. This 
is related to the observation that the DAC FI increases with increasing SDS 
concentration and reaches a maximum close to the critical micelle 
concentration of SDS (6 mM) [25, 26], which is advantageous for increasing 
the effective absorption cross section of the complex causing increase of 
molar absorbancy index [27]. 
 
 
 
Figure 8. Effect of SDS concentration on the fluorescence intensity of 30 ng/mL 
DAC. 
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3.1.6. Effect of time  
The effect of mixing time between DAC and SDS on the FI of DAC was studied 
over time intervals ranging from five minutes up to 30 minutes. It was found that 
the enhancement of the FI was immediately developed and remained stable for 
30 minutes as shown in Figure 9.  Also, the effect of time on the FI of DAC was 
studied and it was found that the enhancement of the FI was immediately 
developed and remained stable for more than 2 hrs.  
 
 
 
Figure 9. Effect of time on the fluorescence intensity of 30 ng/mL DAC in 1% 
SDS micellar media. 
 
3.2. Validation of the micellar enhanced spectrofluorimetric method  
The validity of the proposed method was assessed by studying the following 
parameters: linearity, range, LOD, LOQ, precision, accuracy, robustness and 
specificity, according to ICH guidelines [28]. 
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3.2.1. Linearity and Range 
A linear relationship between DAC concentration and native fluorescence was 
obtained over the concentration range of 12.93-161.60 ng/mL as shown in Figure 
10. The results showed good linearity with regression parameters calculated 
according to ICH guidelines as in Table 1. The regression equations were 
computed and found to be:  FI = 3.777 C + 73.877, (R2 = 0.9993) where C is the 
DAC concentration in ng/mL. The linearity of the calibration graph is indicated 
by the high correlation coefficient (R) value and the small value of residual 
standard deviation (Sy / x) which measures the extent of deviation of the actual 
data points from the regression line. 
 
The limit of quantitation (LOQ) was determined by establishing the lowest 
concentration that can be measured according to ICH recommendations. The limit 
of detection (LOD) was determined by evaluating the lowest concentration of the 
analyte that can be readily detected. The values of LOQ and LOD were calculated 
according to the following equations: 
                      LOQ = 10 σ / S and LOD = 3.3 σ / S 
where σ = the residual standard deviation of the response and S = slope of the 
calibration curve.  The measured LOQ and LOD values are included in Table 1. 
The proposed method was evaluated by calculating accuracy as percent relative 
error and precision as percent relative standard deviation, the results are shown 
in Table 1.  
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Table 1. Regression parameters obtained from the calibration curve of DAC in 
1% SDS micellar media. RSD is the relative standard deviation and SE is the 
standard error. 
 
Parameter Results 
Concentration range (ng/ml) 12.93-161.60 
Limit of detection 1.749 
Limit of quantification 5.30 
Correlation coefficient 0.9993 
Slope 3.777 
Intercept 73.877 
Standard deviation of residuals 2.00 
S.D. of intercept (Sa)  4.89 
S.D. of slope (Sb) 0.05   
%RSD(SD X 100/X’)SD=2.37, x’ 99.4 2.38 
%error 0.97 
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(A)                                                        (B) 
     
 
Figure 10. (A) Calibration curve of (12.93-161.60 ng/mL) DAC using 1 % SDS, 
(B) Emission spectra of DAC (12.93-161.60 ng/mL) in aqueous SDS after 
excitation at 300 nm. 
 
3.2.2.  Accuracy and Precision 
To prove the accuracy of the developed spectrofluorimetric method, the results 
of the assay of DAC in pure form, dosage form and spiked human plasma were 
compared with those obtained using a previously reported spectrofluorimetric 
method [16]. Statistical comparison of the results obtained by the proposed 
method and those obtained by the reported method using mean recoveries, 
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Student’s t-test and variance ratio F-test revealed no significant difference 
between the two methods regarding accuracy and precision as shown in Table 2, 
indicating high accuracy and precision of the proposed method. 
 
 
Table 2 : Statistical analysis of the results of DAC in pure form in 1% SDS  
micellar media , compared with Comparison method. 
 
Parameter proposed method Comparison method [16] 
  
ng/mL 
taken 
ng/mL 
found 
% Recovery 
ng/mL 
taken 
ng/mL 
found 
% Recovery 
12.93 12.36 95.58 10.00 10.27 102.70 
25.86 25.47 98.52 12.00 12.21 101.75 
77.60 79.05 101.87 15.00 14.81 98.73 
96.96 96.54 99.57 18.00 17.98 99.89 
129.28 131.77 101.92 20.00 19.47 97.35 
161.60 159.95 98.98    
Mean (X) 99.42 100.08 
± SD 2.37 2.17 
No of 
experiments 
6 5 
Variance 5.60 4.74 
FF-test 1.18      (6.25)  ٭   
 
Students t-
test   
0.47    ( 2.26 )* 
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*N.B. Figures between parentheses are the tabulated F and t values respectively at  P = 0.05 [29]. 
 
3.2.3. Repeatability 
The repeatability (intraday precision) was evaluated through replicate analysis of 
the studied drug in pure form and in spiked human plasma using three different 
concentrations (25.00, 77.60 and 129.28 ng/mL) and in a Daklanork tablet ® 
using three different concentrations (30.00, 60.00 and 75.00 ng/mL). Each 
concentration was measured three successive times and the results are 
summarized in Table 3.  
 
3.2.4. Intermediate Precision 
The Intermediate Precision (inter-day precision) was evaluated through replicate 
analysis of the studied drug in pure form and in tablet on three successive days. 
The results are juxtaposed in Table 3. The precision of the proposed method was 
fairly high, as indicated by the low values of SD and %RSD, respectively. Also, 
the inter-day and intra-day accuracy was proved by the low values of % E. 
 
3.2.5. Specificity  
The specificity of the proposed spectrofluorimetric method was proven by its 
ability to determine DAC in both a pharmaceutical preparation and plasma 
without interference from excipients or preservatives that commonly present in 
the matrix and plasma content. 
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3.2.6. Stability of reference and working solutions  
Solutions of the drug were stable for two weeks when kept in the refrigerator. No 
change in the FI appeared throughout the whole validation procedures. 
 
3.2.7.  Robustness of the method  
The robustness of the proposed method was demonstrated by the constancy of 
the FI with minor changes in the experimental conditions, such as SDS volume 
2.00 + 0.05 mL. These minor changes that may take place during the 
experimental operation did not affect the FI. 
 
3.3. Application 
3.3.1.  Determination of DAC in pharmaceutical dosage form 
The proposed method after sample pre-treatment as discussed before under 
section 2.4.2. was successfully used to quantify DAC in pharmaceutical dosage 
form (Daklanork® tab) as shown in Table 3.   A standard addition technique was 
used to assess the matrix effect of the tablet additives and its contribution in the 
deviation of the results obtained by the proposed method as shown in Table 4. 
The obtained results revealed no significant matrix effect. 
 
3.3.2. Determination of DAC in spiked human plasma  
The proposed method after sample pretreatment as discussed before under section 
2.4.3. was successfully used to determine DAC in spiked human plasma as shown 
in Table 5. Standard addition technique was used to assess the matrix effect of 
the plasma and its contribution in the deviation of the results obtained by the 
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proposed methods, the obtained results revealed no significant matrix effect (see 
Table 5). Table 3A. Repeatability and reproducibility precision data of the 
proposed spectrofluorimetric method for the determination of DAC in pure, 
dosage form (Daklanork® tablet (60 mg DAC/tab) and spiked human plasma. 
Precision Conc.(ng/mL) Pure form plasma 
Intra-day 
precision 
25.00 98.30 + 1.68 93.46 + 1.85 
77.60 101.37+ 1.10 
 
98.62 + 1.97 
129.28 100.15 + 0.82 
 
96.04 + 0.96 
Inter-day 
precision 
25.00 98.78 + 2.01 94.52 + 1.71 
77.60 101.76+ 1.14 
 
97.12 + 1.55 
129.28 100.45+ 0.56 
 
95.25 + 1.25 
 
Table 3B. Repeatability and reproducibility precision data of the proposed 
spectrofluorimetric method for the determination of DAC in dosage form 
(Daklanork® tablet (60 mg DAC/tab). 
 
Precision Conc.(ng/mL) Dosage form 
Intra-day 
precision 
30.00 103.28 + 1.01 
 60.00 101.90 + 1.47 
 75.00 102.17+ 1.02 
 Inter-day 
precision 
30.00 103.84 + 1.01 
 60.00 100.85 + 1.52 
 75.00 101.64 + 1.44 
 * Each result is the average of three different separate determinations. 
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Table 4. Results obtained by applying the proposed method for the determination 
of DAC in Daklanork® tab (60 mg DAC/tab) dosage form and results obtained 
by applying standard addition technique. 
 Assay Amount taken 
(ng/mL) 
Amount of st added 
(ng/mL) 
% found 
 
% found  
       
100.02 
 
 
 
 
65.00 
0.00 101.20 
103.10 
 
 
52.00 102.59 
100.47 
 
88.00 99.68 
Mean + SD 101.20 + 1.36 Mean + SD  101.16 + 1.19 
%RSD 1.34 %RSD 1.17 
*Each result is the average of three different separate determinations 
 
Table 5. Results obtained by applying the proposed method for the determination 
of DAC in spiked plasma and results obtained by applying standard addition 
technique. 
 Assay Amount taken 
(ng/mL) 
Amount of standard 
added (ng/mL) 
% found 
 
% found  
93.30  
 
55.12 
 
0.00 
95.42 
94.76 36.00 94.20 
98.20 66.00 96.94 
Mean + SD 95.42 + 2.52 Mean + SD  95.52 + 1.37 
%RSD 2.64 %RSD 1.44 
*Each result is the average of three different separate determinations. 
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3.4. Mechanism of the micellar enhancement effect of SDS on DAC HCl 
fluorescence 
 To establish whether the sensitization process of DAC fluorescence was only due 
to an increase in quantum yield, or whether it was affected by an increase in 
absorption at the excitation wavelength, the molar absorptivity (ε) of DAC in the 
presence of SDS was determined at 300 nm excitation. Table 6 shows that the ε 
micelle: ε water ratio was approximately 1.0, which indicates that the increase in 
sensitivity is not affected by an increase in the light absorption of the studied drug 
but is due to an increase in the quantum yield of DAC.  A likely contributing 
factor here is the protection of the lowest excited singlet state in the micellar 
micro-environment from non-radiative processes [18]. In addition, sequestering 
of the drug into SDS can potentially cause a decrease in non-radiative energy loss 
via molecular collisions resulting in an enhancement of the fluorescence quantum 
efficiency [27]. The optimum concentration of SDS is 6.90 mM which is above 
the critical micelle concentration value (6 mM) showing that the presence of 
micelles significantly enhances the DAC fluorescence intensity [25]. Also, the 
DAC absorption spectrum at 300 nm increased when SDS was added (Table 6), 
which is consistent with the fluorescence enhancement. In future work, 
computational modelling might also reveal better understanding of the 
importance of DAC interactions with polar and non-polar regions of the micelle 
and the effect this has on the density of excited states.   
The forced degradation studies also give information about the chemical 
behaviour of the drug molecule as they are carried out to determine the intrinsic 
stability of a drug substance in formulation. To the best of our knowledge, this 
study is the first reported stability-indicating spectrofluorimetric method for the 
determination of DAC in tablets and spiked human plasma.  
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3.5. Results of stability indicating assay 
DAC was found to be highly labile to alkaline hydrolysis after exposing it in its 
tablet form to alkaline degradation in 0.1 N NaOH, where 28.76% of the drug was 
degraded after 2 hrs and 52.12 %  degradation occurs  after 24 hrs. DAC in its 
dosage form was also exposed to acidic degradation using 0.1 N HCl for 24 hrs 
resulted in  about 25.35 % degradation. 
 
Exposure of DAC in its Daklanork tablet form to oxidative degradation by 30 % 
H2O2 for 24 hrs resulted in about 55% degradation of DAC. Tablets were also 
subjected to 70о C for 3 hrs in a water bath. Mild degradation (20%) was observed 
which indicates that DAC in its tablet form is thermally stable. Exposing DAC in 
capsules to sunlight also revealed that it is strongly affected by sunlight after 
exposure for 24 hrs.  
 
 
Table 6: Determination of the molar absorptivity of DAC HCl in aqueous and 
micellar media:  
Concentration 
taken (μg/mL) 
Absorbance In 
aqueous 
medium at 
300 nm 
ε water Absorbance In 
micellar 
medium at 
300 nm 
ε 
micellar 
ε micellar 
________  
ε water 
16 0.628 31863 0.76 35618 1.12 
8 0.351 35618 0.419 42518 1.19 
4.5 0.177 31931 0.213 38426 1.20 
13 0.5053 31554 0.573 35782 1.13 
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4. Conclusion 
In this article, we have developed and optimized a new spectrofluorimetric assay 
for DAC combined with a micellar enhancement of the fluorescence signal. The 
fact that our methodology is optimal in water rather than common organic 
solvents such as methanol leads to a greener chemistry approach as well as being 
simple, precise, accurate, economical and robust. Furthermore, it can be applied 
for the determination of DAC in bulk drug, tablet content and in spiked human 
plasma.  The results shown in this work indicate the validity of our approach for 
application in routine quality control analysis since it is characterized by 
clinically-relevant sensitivity, selectivity and simplicity.  
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